Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

doi:10.1016/j.ccell.2022.06.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

Cancer cell - 11 Jul 2022

Elamin Yasir Y, Robichaux Jacqulyne P, Carter Brett W, Altan Mehmet, Tran Hai, Gibbons Don L, Heeke Simon, Fossella Frank V, Lam Vincent K, Le Xiuning, Negrao Marcelo V, Nilsson Monique B, Patel Anisha, Vijayan R S K, Cross Jason B, Zhang Jianjun, Byers Lauren A, Lu Charles, Cascone Tina, Feng Lei, Luthra Rajyalakshmi, San Lucas Francis A, Mantha Geeta, Routbort Mark, Blumenschein George, Tsao Anne S, Heymach John V

Abstract excerpt

We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The study achieved its primary endpoint, with confirmed objective response rates (ORRs) of 32% and 31% by investigator and blinded independent review, respectively, with a median progression-free survival of 5.5 months. Using preclinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Treatment Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Exons

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 35820397
DOI: 10.1016/j.ccell.2022.06.006
PMCID: PMC9667883

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.PMID 35820397Read ↗

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Semantic proximity Read ↗

The Clinical Pathological Spectrum and Prognosis of NSCLC with EGFR Exon20 InsertionsSemantic proximity Read ↗

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.Semantic proximity Read ↗

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung CancerSemantic proximity Read ↗

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].Semantic proximity Read ↗

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).Semantic proximity Read ↗

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.Semantic proximity Read ↗

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.